Research Article

In vitro AND in silico EVALUATION OF THYMOQUINONE AS POTENTIAL ANTICANCER AGENT IN HUMAN ACUTE MYELOID LEUKEMIA HL-60 CELLS

Volume: 23 Number: 1 April 15, 2022
TR EN

In vitro AND in silico EVALUATION OF THYMOQUINONE AS POTENTIAL ANTICANCER AGENT IN HUMAN ACUTE MYELOID LEUKEMIA HL-60 CELLS

Abstract

This study aims to explore the cytotoxic, apoptotic and autophagic effects of thymoquinone on human acute myeloid leukemia. The cytotoxic effects of thymoquinone were determined with 3-(4, 5-dimethylthiazol-2-yl)-2 and 5-diphenyltetrazolium bromide (MTT) tests. B-cell lymphoma 2 associated X protein (Bax), B-cell lymphoma 2 (Bcl-2), caspase 3, mammalian target of rapamycin (mTOR), phosphatidylinositol-3-kinase (PI3K), and protein kinase B (AKT) gene expression analyzes were studied with quantitative real-time polymerase chain reaction (qRT-PCR). AutoDock Tools 4.2 software was applied to research the potential binding of thymoquinone in the active sites of Bax, Bcl-2, caspase 3, mTOR, PI3K, and AKT proteins. Thymoquinone caused a cytotoxic effect on HL-60 cells (Human leukemia cell line) with a value of 16.35 µM. Bcl-2 expression was decreased in all concentrations applied compared to the control. A decrease in caspase 3 expression level was detected in the cells treated with 10 µM, 15 µM, and 25 µM thymoquinone compared to the control. Thymoquinone induced an important decrease in mTOR and PI3K expressions compared to the control at all doses, while AKT decreased at a dose of 15 µM. The docking outcomes showed that thymoquinone interacts with the active site amino acids of apoptotic and autophagic proteins via hydrophobic interactions and hydrogen bonding. The present findings suggest that thymoquinone can stimulate autophagy by prevention of PI3K/AKT/mTOR pathway in HL-60 cells and may become a new target for the therapy of acute myeloid leukemia.

Keywords

Supporting Institution

Aksaray üniversitesi

Project Number

2017-058

Thanks

This study was financed by Aksaray University Scientific Research Fund (grant number 2017-058). We are thankful to Aksaray University Scientific and Technological Application and Research Center for the use of the Molecular Biology and Metabolism Laboratory. I would like to thank Biotechnologist Mehmet KARATAŞ for his kind help in the determination of molecular docking study.

References

  1. 1. Ahmad, A., Husain, A., Mujeeb, M., Khan, S.A., Najmi, A.K., Siddique, N.A., Damanhouri, Z.A. & Anwar, F. 2013. A review on therapeutic potential of Nigella sativa: A miracle herb. Asian Pacific Journal of Tropical Biomedicine, 3: 337-352.
  2. 2. Al-Otaibi, N.A.S., Cassoli, J.S., Slater, N.K.H. & Rahmounc, H. 2019. Molecular characterization of human leukemia 60 (HL-60) cells as a model of acute myelogenous leukemia post cryopreservation. Methods in Molecular Biology, 1916: 239-247.
  3. 3. Artun, F.T. & Karagöz, A. 2021. Antiproliferative and apoptosis inducing effect of the methanolic extract of Centaurca hermannii in human cervical cancer cell line. Biotechnic and Histochemistry, 96:1-10.
  4. 4. Aykaç, A., Gören, M.Z. & Cabadak, H. 2015. Altered ratio of proapoptotic and antiapoptotic proteins in different brain regions of female rats in model of post-traumatic stress disorder. Turkish Journal of Biochemistry, 40: 1-7.
  5. 5. Banerjee, S., Kascb, A.O., Wang, Z., Kong, D., Mohammed, M., Padhye, S., Sarkar, F.H. & Mohammed, R.M. 2009. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Research, 69: 5575-5583.
  6. 6. Bashmail, H.A., Alamoudi, A.A., Noorwali, A., Hegazy, G.A., AJabnoor, G.M. & Al-Abd, A.M. 2020. Thymoquinone enhances paclitaxel anti-breast cancer activity via inhibiting tumor-associated stem cells despite apparent mathematical antagonism. Molecules, 25: 426.
  7. 7. Bashmail, H.A., Alamoudi, A.A., Noorwali, A., Hegazy, G.A., AJabnoor, G.M., Choundhry, H. & Al-Abd, A.M. 2018. Thymoquinone synergizes gemcitabine anti-breast cancer activity via modulating its apoptotic and autophagic activities. Scientific Reports, 8: 11674.
  8. 8. Chang, C.H., Lee, C.H., Lu, C.C., Tsai, F.J., Hsu, Y.M., Tsao, J., Juan, Y.N., Chiu, H.Y., Yang, J.S. & Wang, C.C. 2017. Resveratrol-induced autophagy and apoptosis in cisplatin-resistant human oral cancer CAR cell: A key role of AMPK and AKT/mTOR signaling. International Journal of Oncology, 50: 873-882.

Details

Primary Language

English

Subjects

Structural Biology

Journal Section

Research Article

Publication Date

April 15, 2022

Submission Date

September 23, 2021

Acceptance Date

January 5, 2022

Published in Issue

Year 2022 Volume: 23 Number: 1

APA
Tekin Karacaer, N. (2022). In vitro AND in silico EVALUATION OF THYMOQUINONE AS POTENTIAL ANTICANCER AGENT IN HUMAN ACUTE MYELOID LEUKEMIA HL-60 CELLS. Trakya University Journal of Natural Sciences, 23(1), 53-63. https://doi.org/10.23902/trkjnat.999403
AMA
1.Tekin Karacaer N. In vitro AND in silico EVALUATION OF THYMOQUINONE AS POTENTIAL ANTICANCER AGENT IN HUMAN ACUTE MYELOID LEUKEMIA HL-60 CELLS. Trakya Univ J Nat Sci. 2022;23(1):53-63. doi:10.23902/trkjnat.999403
Chicago
Tekin Karacaer, Neslihan. 2022. “In Vitro AND in Silico EVALUATION OF THYMOQUINONE AS POTENTIAL ANTICANCER AGENT IN HUMAN ACUTE MYELOID LEUKEMIA HL-60 CELLS”. Trakya University Journal of Natural Sciences 23 (1): 53-63. https://doi.org/10.23902/trkjnat.999403.
EndNote
Tekin Karacaer N (April 1, 2022) In vitro AND in silico EVALUATION OF THYMOQUINONE AS POTENTIAL ANTICANCER AGENT IN HUMAN ACUTE MYELOID LEUKEMIA HL-60 CELLS. Trakya University Journal of Natural Sciences 23 1 53–63.
IEEE
[1]N. Tekin Karacaer, “In vitro AND in silico EVALUATION OF THYMOQUINONE AS POTENTIAL ANTICANCER AGENT IN HUMAN ACUTE MYELOID LEUKEMIA HL-60 CELLS”, Trakya Univ J Nat Sci, vol. 23, no. 1, pp. 53–63, Apr. 2022, doi: 10.23902/trkjnat.999403.
ISNAD
Tekin Karacaer, Neslihan. “In Vitro AND in Silico EVALUATION OF THYMOQUINONE AS POTENTIAL ANTICANCER AGENT IN HUMAN ACUTE MYELOID LEUKEMIA HL-60 CELLS”. Trakya University Journal of Natural Sciences 23/1 (April 1, 2022): 53-63. https://doi.org/10.23902/trkjnat.999403.
JAMA
1.Tekin Karacaer N. In vitro AND in silico EVALUATION OF THYMOQUINONE AS POTENTIAL ANTICANCER AGENT IN HUMAN ACUTE MYELOID LEUKEMIA HL-60 CELLS. Trakya Univ J Nat Sci. 2022;23:53–63.
MLA
Tekin Karacaer, Neslihan. “In Vitro AND in Silico EVALUATION OF THYMOQUINONE AS POTENTIAL ANTICANCER AGENT IN HUMAN ACUTE MYELOID LEUKEMIA HL-60 CELLS”. Trakya University Journal of Natural Sciences, vol. 23, no. 1, Apr. 2022, pp. 53-63, doi:10.23902/trkjnat.999403.
Vancouver
1.Neslihan Tekin Karacaer. In vitro AND in silico EVALUATION OF THYMOQUINONE AS POTENTIAL ANTICANCER AGENT IN HUMAN ACUTE MYELOID LEUKEMIA HL-60 CELLS. Trakya Univ J Nat Sci. 2022 Apr. 1;23(1):53-6. doi:10.23902/trkjnat.999403